Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04696731
Title Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics
Indications

renal cell carcinoma

Therapies

ALLO-647 + Cyclophosphamide + Fludarabine

ALLO-316

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.